Publications by authors named "Benit Maru"

Claim this Profile
S
Severe communication delays are independent of seizure burden and persist despite contemporary treatments in SCN1A+ Dravet syndrome: Insights from the ENVISION natural history study.
M Scott Perry, Ingrid E Scheffer, Joseph Sullivan, Andreas Brunklaus, Susana Boronat, Benit Maru

Epilepsia· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The clinical, economic, and humanistic burden of Dravet syndrome - A systematic literature review.
Joseph Sullivan, Alison M Deighton, Maria Candida Vila, Shelagh M Szabo, Benit Maru

Epilepsy Behav· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An updated cost-utility model for onasemnogene abeparvovec (Zolgensma®) in spinal muscular atrophy type 1 patients and comparison with evaluation by the Institute for Clinical and Effectiveness Review (ICER).
Rebecca Dean, Ivar Jensen, Phil Cyr, Beckley Miller, Benit Maru

J Mark Access Health Policy· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to: Alfred Sandrock, Wildon Farwell. Letter to the Editor, Comparisons Between Separately Conducted Clinical Trials: Letter to the Editor Regarding Dabbous O, Maru B, Jansen JP, Lorenzi M, Cloutier M, Guérin A, et al. Adv Ther (2019) 36(5):1164-76. doi:10.1007/s12325-019-00923-8.
Omar Dabbous, Benit Maru, Jeroen P Jansen, Maria Lorenzi, Martin Cloutier

Adv Ther· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survival, Motor Function, and Motor Milestones: Comparison of AVXS-101 Relative to Nusinersen for the Treatment of Infants with Spinal Muscular Atrophy Type 1.
Omar Dabbous, Benit Maru, Jeroen P Jansen, Maria Lorenzi, Martin Cloutier

Adv Ther· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness analysis of using onasemnogene abeparvocec (AVXS-101) in spinal muscular atrophy type 1 patients.
Daniel C Malone, Rebecca Dean, Ramesh Arjunji, Ivar Jensen, Phil Cyr, Benit Maru

J Mark Access Health Policy· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy.
Samiah Al-Zaidy, A Simon Pickard, Kavitha Kotha, Lindsay N Alfano, Linda Lowes, Benit Maru

Pediatr Pulmonol· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Successful treatment of a patient with severe atopic dermatitis and severe asthma by centrifugal therapeutic plasma exchange.
Louise Fuller, Benit Maru, Neil Isserlis, Rino Cerio

BMJ Case Rep· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potential use of an estrogen-glucocorticoid receptor chimera as a drug screen for tissue selective estrogenic activity.
Benit S Maru, Jonathan H Tobias, Caroline Rivers, Christopher J Caunt, Michael R Norman

Bone· January 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis